A physician's view of pharmacogenetics, RxReady, and safer medication decisions.
A familiar scene in medicine: three patients receive the same medication for the same clinical problem. One improves quickly. One feels nothing. One develops side effects and stops the treatment after a few days.
This is not rare. It is part of daily practice.
Of course, medication response is never about genes alone. Age, kidney function, liver function, body weight, other medicines, alcohol use, smoking, diet, adherence, and the disease itself can all change the outcome. But genetics can be one of the missing pieces, especially when a medicine is processed through pathways that vary from person to person.
Pharmacogenetics studies how inherited genetic differences may affect medication response. Some medicines need to be activated in the body before they work. Some are cleared by enzymes that move faster in one person and slower in another. Some are transported into or out of tissues by proteins that can vary genetically. A standard dose may be right for the average patient and still be too much, too little, or simply wrong for a particular person.
RxReady, the pharmacogenetic test we offer with Nala Genetics, is designed to give the treating clinician additional information about how a patient's DNA may affect their interaction with certain medicines. That phrase, additional information, is deliberate. The report supports the prescriber. It does not replace the prescriber.
When patients first hear about pharmacogenetics, they often imagine a report that says, 'Take this drug, never take that drug.' Real medicine is more careful than that. A useful pharmacogenetic report may suggest standard dosing, closer monitoring, a lower or higher starting dose, or a different medication when the drug-gene evidence supports that decision. In the RxReady report structure, those kinds of follow-up actions are organized so the clinician can see what deserves attention first.
That structure is helpful because most patients do not take one medication in isolation. A patient may be on a blood pressure medicine, a cholesterol medicine, an antidepressant, a pain medicine, and an acid-suppressing drug. Another may be starting cancer treatment. Another may have had three medication failures before anyone asks whether metabolism could be part of the story.
Pharmacogenetics does not answer every medication question. It will not explain every side effect. It does not remove the need for clinical monitoring. It does not cover every drug in existence. It also does not mean that a patient should stop a medication just because a result appears in a colored box.
This point is worth saying plainly: do not change, stop, or start a medication based only on a genetic report. Bring the report to the physician who manages that treatment.
Why so cautious? Because the same genetic result can mean different things in different clinical situations.
A patient who is stable on a medicine, with good response and no side effects, is not the same as a patient who is about to start that medicine for the first time. A patient with kidney disease is not the same as a healthy adult. A patient taking five interacting medicines is not the same as a patient taking one. In some cases, the best action is to change the plan. In others, it is to monitor more closely. Sometimes the right choice is to document the result and do nothing today.
This is where the physician's role becomes even more valuable, not less. Genetic data has to be translated into the reality of the person. What diagnosis are we treating? How urgent is treatment? Are there safe alternatives? Has the patient already responded well? Are there lab markers we can follow? Is the drug affected by food, alcohol, liver disease, kidney disease, or another prescription?
I also tell patients that pharmacogenetic results can have value beyond one appointment. Your DNA does not change in the usual clinical sense. But your medications will change over a lifetime. A result that does not matter today may matter before a surgery, after a new diagnosis, or when a specialist considers a new treatment years later. For that reason, a pharmacogenetic report should not be forgotten in an email attachment. It should become part of the patient's medication history.
There is another reason this matters: patients remember medication harm. A bad side effect can make a person afraid of treatment for years. When we can reduce avoidable trial and error, we protect trust as much as we protect physiology.
As a founder and physician, I do not want pharmacogenetics to be sold as a futuristic gadget. I want it to become a practical clinical habit: before we prescribe, we ask whether the patient's biology gives us information that should change the plan. If it does, we use it. If it does not, we say so.
The goal is not more medication. The goal is better-matched medication.
One prescription will never be the same story in every patient. Pharmacogenetics helps us respect that fact earlier, instead of discovering it only after the patient has suffered through failure or side effects.